Ublituximab trials for Multiple Sclerosis (MS) - Relapsing-remitting

All Ublituximab trials · All Multiple Sclerosis (MS) - Relapsing-remitting trials

Phase breakdown

Recruiting trials studying Ublituximab for Multiple Sclerosis (MS) - Relapsing-remitting

• Effects of Ublituximab on Motor Functions in Multiple Sclerosis
  NCT06629428 · Phase: Early Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
  NCT06864936 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
  NCT07225361 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Ublituximab for Multiple Sclerosis (MS) - Relapsing-remitting?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.